Related Experiment Video
Updated: Feb 28, 2026
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
Upregulation of Circulating miR-195-3p in Heart Failure
1Department of Pathology, Shenzhen Sun Yat-Sen Cardiovascular Hospital, Shenzhen, China.
Objectives:
Many circulating microRNAs (miRs) have been shown to have potential biomarker effects in cardiovascular disease. We studied the dysregulation of circulating miR-195-3p in patients with heart failure (HF) to elucidate its value as a potential biomarker for HF.
Methods:
Eight ischemic HF (IHF) patients, 8 nonischemic HF patients (NIHF), and 8 healthy volunteers (matched by age and sex - normal controls [NCs]) were chosen for miR sequencing. The plasma RNA was extracted, and a small RNA library of HF was established and then sequenced using next-generation sequencing (NGS) technology. The miR-195-3p was selected for a second clinical study in 60 IHF, 48 NIHF patients, and 35 NCs for qRT-PCR validation.
Results:
The expression of circulating miR-195-3p in the IHF group was increased 69.5-fold compared with the NC group using NGS technique, and it was the most elevated in all upregulated miRs. MiR-195-3p was ranked in the top 1 of all upregulated miRs in contribution to HF based on a random forest model analysis. The upregulation of circulating miR-195-3p was also validated with the qRT-PCR method, and receiver operating characteristic curve analysis showed that the area under the curve (AUC) was 0.831.
Conclusions:
The circulating miR-195-3p was upregulated in IHF and NIHF patients and could be a potential biomarker for HF.
Insights
Circulating miR-195-3p is significantly upregulated in heart failure (HF) patients. This microRNA shows potential as a novel biomarker for diagnosing HF.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Medicine
Background:
- Circulating microRNAs (miRs) are increasingly recognized for their potential as biomarkers in cardiovascular diseases.
- Heart failure (HF) diagnosis and management can benefit from novel, reliable biomarkers.
Purpose of the Study:
- To investigate the dysregulation of circulating miR-195-3p in patients with heart failure (HF).
- To determine the potential of miR-195-3p as a biomarker for HF.
Main Methods:
- Plasma RNA was extracted from patients with ischemic HF (IHF), non-ischemic HF (NIHF), and healthy controls (NCs).
- Next-generation sequencing (NGS) was used to profile microRNA expression.
- Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was employed for validation of miR-195-3p levels.
- Random forest models and receiver operating characteristic (ROC) curve analysis were utilized.
Main Results:
- Circulating miR-195-3p expression was markedly increased (69.5-fold) in IHF patients compared to NCs via NGS.
- MiR-195-3p was identified as the most significantly upregulated microRNA contributing to HF by random forest analysis.
- qRT-PCR validation confirmed the upregulation of miR-195-3p in HF patients.
- ROC curve analysis yielded an area under the curve (AUC) of 0.831, indicating good diagnostic potential.
Conclusions:
- Circulating miR-195-3p is significantly upregulated in both IHF and NIHF patients.
- MiR-195-3p demonstrates potential as a valuable biomarker for the diagnosis of heart failure.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
01:20Mitral Regurgitation I: Introduction
01:17Pathophysiology of Heart Failure
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Heart Failure III: Clinical Manifestations
01:26Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...